Quantitative mass spectrometry of urinary biomarkers

DOI: 10.5584/jiomics.v4i2.177

Authors

  • Marina Jerebtsova Department of Microbiology, Howard University College of Medicine, 520 W Street N.W., Washington, DC 20059, USA
  • Sergei Nekhai Center for Sickle Cell Disease, Howard University College of Medicine, 520 W Street N.W., Washington, DC 20059, USA

Abstract

The effectiveness of treatment of renal diseases is limited because the lack of diagnostic, prognostic and therapeutic markers. Despite the more than a decade of intensive investigation of urinary biomarkers, no new clinical biomarkers were approved. This is in part because the early expectations toward proteomics in biomarkers discovery were significantly higher than the capability of technology at the time. However, during the last decade, proteomic technology has made dramatic progress in both the hardware and software methods. In this review we are discussing modern quantitative methods of mass-spectrometry and providing several examples of their applications for discovery and validation of renal disease biomarkers. We are optimistic about future prospects for the development of novel of specific clinical urinary biomarkers.

Downloads

Published

2021-02-23